Richard Pratley

1.8k total citations · 3 hit papers
9 papers, 997 citations indexed

About

Richard Pratley is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Molecular Biology. According to data from OpenAlex, Richard Pratley has authored 9 papers receiving a total of 997 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 2 papers in Nephrology and 1 paper in Molecular Biology. Recurrent topics in Richard Pratley's work include Diabetes Treatment and Management (6 papers), Diabetes Management and Research (3 papers) and Chronic Kidney Disease and Diabetes (2 papers). Richard Pratley is often cited by papers focused on Diabetes Treatment and Management (6 papers), Diabetes Management and Research (3 papers) and Chronic Kidney Disease and Diabetes (2 papers). Richard Pratley collaborates with scholars based in United States, Denmark and Australia. Richard Pratley's co-authors include Kenneth W. Mahaffey, Johannes F.E. Mann, Peter Rossing, Thomas Idorn, George L. Bakris, Katherine R. Tuttle, Heidrun Bosch‐Traberg, Florian M.M. Baeres, Nanna L. Lausvig and Vlado Perkovic and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Diabetes Care.

In The Last Decade

Richard Pratley

9 papers receiving 975 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

2024 656 citations Vlado Perkovic, Katherine R. Tuttle et al. New England Journal of Medicine profile →
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

2023 147 citations Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation profile →
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials

2024 123 citations Mikhail Kosiborod, John Deanfield et al. The Lancet profile →

Peers

Richard Pratley

EDM

SURGE

CCM

PHARM

Vlado Perkovic Australia

Nanna L. Lausvig Denmark

Heidrun Bosch‐Traberg Denmark

Ronnie Har Canada

Zin Zin Htike United Kingdom

Marta Seghieri Italy

Francis Chun Chung Chow Hong Kong

Kerensa Thorne United Kingdom

Albert Fung United States

Silvina Gallo United States

Vlado Perkovic Australia

Richard Pratley

592 ×0.8

EDM

176 ×0.8

SURGE

161 ×0.8

141 ×0.7

CCM

151 ×0.8

PHARM

Citations per year, relative to Richard Pratley Richard Pratley (= 1×) peers Vlado Perkovic

Countries citing papers authored by Richard Pratley

Since Specialization

Citations

This map shows the geographic impact of Richard Pratley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Pratley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Pratley more than expected).

Fields of papers citing papers by Richard Pratley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Pratley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Pratley. The network helps show where Richard Pratley may publish in the future.

Co-authorship network of co-authors of Richard Pratley

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Pratley. A scholar is included among the top collaborators of Richard Pratley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Pratley. Richard Pratley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Boeder, Schafer, Michael J. Davies, Janet B. McGill, et al.. (2024). Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technology & Therapeutics. 26(9). 618–625. 10 indexed citations

Perkovic, Vlado, Katherine R. Tuttle, Peter Rossing, et al.. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 391(2). 109–121. 656 indexed citations breakdown →

Kosiborod, Mikhail, John Deanfield, Richard Pratley, et al.. (2024). Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. The Lancet. 404(10456). 949–961. 123 indexed citations breakdown →

Rossing, Peter, Florian M.M. Baeres, George L. Bakris, et al.. (2023). The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrology Dialysis Transplantation. 38(9). 2041–2051. 147 indexed citations breakdown →

Perkovic, Vlado, Florian M.M. Baeres, George L. Bakris, et al.. (2022). FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation. 37(Supplement_3). 3 indexed citations

Persson, Frederik, Ofri Mosenzon, Hiddo J.L. Heerspink, et al.. (2021). Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Diabetes Care. 44(4). 1020–1026. 43 indexed citations

Perkovic, Vlado, Stephen C. Bain, George L. Bakris, et al.. (2019). FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation. 34(Supplement_1). 6 indexed citations

Perkovic, Vlado, Stephen C. Bain, George L. Bakris, et al.. (2019). SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation. 34(Supplement_1). 4 indexed citations

Perkovic, Vlado, Stephen C. Bain, George L. Bakris, et al.. (2019). FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER. Nephrology Dialysis Transplantation. 34(Supplement_1). 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact